N@N

Obagi Medical Products to Present at Two Investor Conferences in January

_{//health-fitness.news-articles.net/content/2009/ .. sent-at-two-investor-conferences-in-january.html}
^{Published in Health and Fitness on Monday, January 5th 2009 at 5:16 GMT, Last Modified on 2009-01-05 05:16:41 by Market Wire}  

LONG BEACH, Calif.--([ BUSINESS WIRE ])--Obagi Medical Products, Inc. (Nasdaq:OMPI), a leader in topical aesthetic and therapeutic skin health systems, announced today that Company management will present a corporate overview at the following two investor conferences:

• The 11th Annual ICR XChange Conference to be held on January 14-15, 2009 at the St. Regis Monarch Beach Resort in Dana Point, Calif. The presentation will take place at 8:50 am (PST) on Wednesday, January 14, 2009.
• The 27th Annual JP Morgan Healthcare Conference to be held on January 12-15, 2009 at the Westin St. Francis in San Francisco, Calif. The presentation will take place at 12:30 pm (PST) on Thursday, January 15, 2009.

A live webcast of the JP Morgan presentation will be available via the Internet by visiting the investor relations section of the Company's web site at [ www.obagi.com ]. The archived presentation will be available on the web site for 30 days.

About Obagi Medical Products, Inc.

Obagi Medical Products develops and commercializes skin health products for the dermatology, plastic surgery, and related aesthetic markets. Using its Penetrating Therapeutic™ technologies, Obagi Medical's products are designed to improve penetration of agents across the skin barrier for common and visible skin conditions in adult skin including chloasma, melasma, senile lentigines, acne vulgaris and sun damage. The history of Obagi's skin care product introductions is as follows: Obagi Nu-Derm®, 1988; Obagi-C® Rx (the first and only prescription-strength vitamin C and hydroquinone system), 2004; Obagi® Professional-C (a line of highly stable vitamin C serums), 2005; Obagi® Condition and Enhance for use with cosmetic procedures to enhance patient outcomes and satisfaction, 2006; Obagi ELASTIderm™ eye treatment and Obagi CLENZIderm® M.D. acne therapeutic systems, 2007; a formulation of Obagi CLENZIderm® M.D. Systems for normal to dry skin, June 2007; Obagi ELASTIderm™ Décolletage System, January 2008 and SoluCLENZ™ Rx Gel for the pharmacy channel in August 2008. Visit [ www.obagi.com ] for information.